High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease

Circulation

Volumn 103, Issue 13, 2001, Pages 1813-1818

  Ridker, P M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cardiovascular diseases; Inflammation; Prevention; Risk factors; Screening

Indexed keywords

BIOCHEMICAL MARKER; C REACTIVE PROTEIN;

ALGORITHM; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INFLAMMATION; LABORATORY TEST; LIPID ANALYSIS; OUTPATIENT; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCREENING TEST; STROKE;

EID: 0035799331     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.13.1813     Document Type: Review

References (57)

1. Atherosclerosis: An inflammatory disease
2. Evaluating novel cardiovascular risk factors: Can we better predict heart attacks?
3. C-reactive protein as a cardiovascular risk factor: More than an epiphenomenon?
4. C reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
5. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study
6. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
7. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: Results from the Cardiovascular Health Study and the Rural Health Promotion Project
8. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women
9. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease
10. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (MONItoring trends and determinants in CArdiovascular disease) Augsberg Cohort Study, 1984 to 1992
11. Infections, inflammation, and the risk of coronary heart disease
12. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly
13. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses
14. C-reactive protein: Relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men
15. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina
16. C-reactive protein is a potent predictor of mortality independently and in combination with troponin T in acute coronary syndromes
17. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability
18. Prognostic influence of fibrinogen and C-reactive protein levels in unstable coronary artery disease
19. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease
20. Production of C-reactive protein and risk of coronary events in stable and unstable angina
21. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
22. Molecular bases of the acute coronary syndromes
23. Inflammation, atherosclerosis, and ischemic events: Exploring the hidden side of the moon
24. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
25. Homocyst(e)ine, diet, and cardiovascular diseases: A statement for healthcare professionals from the Nutrition Committee, American Heart Association: ACC/AHA Scientific Advisory
26. Mechanisms of disease: Homocysteine and atherothrombosis
27. Homocysteine and risk of cardiovascular disease among postmenopausal women
28. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians
29. Homocysteine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial
30. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians
31. Variability in the measurement of C-reactive protein in healthy adults: Implications for reference interval and epidemiologic methods
32. Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum
33. Clinical efficacy of an automated highsensitivity C-reactive protein assay
34. Evaluation of four automated high-sensitivity C-reactive protein methods: Implications for clinical and epidemiological applications
35. Evaluation of nine automated high sensitivity C-reactive protein methods: Implications for clinical and epidemiological applications
36. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults
37. The acute phase response and C-reactive protein
38. Long-term effects of pravastatin on plasma concentration of C-reactive protein
39. Absence of diurnal variation of C-reactive protein levels in healthy human subjects
40. Hormone replacement therapy, inflammation, and hemostasis in elderly women
41. Hormone replacement therapy and increased plasma concentration of C-reactive protein
42. Effect of postmenopausal hormones on inflammation sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study
43. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women
44. Elevated C-reactive protein levels in overweight and obese adults
45. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue?
46. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men
47. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction
48. Long-term exercise and atherogenic activity of blood mononuclear cells in persons at risk of developing ischemic heart disease
49. Body mass index, diabetes, and C-reactive protein among U.S. adults
50. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS)
51. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency
52. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
53. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
54. C-reactive protein in the arterial intima: Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis
55. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease
56. Direct proinflammatory effect of C-reactive protein on human endothelial cells